Lisbon, Portugal - May 8 - 9, 2024

LONGEVITY MEDICINE

Thursday, May 4  | 10:00 am

Longevity Landscape through the Clinical Lens

by Jyothi Devakumar, PhD, Group CSO and Partner at Longevity Tech Fund and Longevity Builders, Palo Alto, CA, USA

Clinicians are always seeking newer and effective ways to help the patients. Emerging science of Longevity offers an opportunity to treat disease even before they develop with novel methods to diagnose, prevent, postpone and even modify the course of disease progression. What stage of clinical development are these new and upcoming therapies in? A peek in to the future of clinical longevity- A decade in the making through the eyes of an investor.

Thursday, May 4  | 10:20 am

Implementation of Longevity focused into a Clinical Setting

by Joanna Bensz, Founder & CEO, Longevity Center Group, Warsaw, Poland

Thursday, May 4  | 10:40 am

Health Longevity Road map in Israel and Sheba Longevity Center

by Tzipi Strauss, Director, Department of Neonatology, Edmond & Lily Safra Children Hospital, Sheba Medical Center, Tel-Hashomer, Israel

Vision and Mission – establishing longevity medicine as a clinical department.

Thursday, May 4  | 11:20 – 11:40 am

Working towards evidence-based Healthy Longevity Medicine

by Andrea Britta Meier, PhD, Co-Director at Centre for Health Longevity, National University Health System, Singapore, Singapore

Thursday, May 4  | 11:40 – 12:00 am

A New Frontier in Hyperbaric Medicine

by Shai Efrati, Director of Sagol Center for Hyperbaric Medicine, Tel Aviv, Israel

Thursday, May 4  | 12:00 – 12:20 pm

Advanced Diagnostics and Treatment in Personalized Healthy Ageing Medicine

by Vicente Mera, MD, Head of Internal and Anti-Aging Medicine, SHA Wellness Clinic, Benidorm, Spain

Thursday, May 4  | 17:30 pm

A breakthrough in immune aging

by Chris Rinsch, PhD, CEO and Co-founder of Amazentis, Lausanne, Switzerland

Thursday, May 4  | 17:50 pm

Aging of the Human Immune System

by Eric Verdin, President & CEO of Buck Institute for Research on Aging, Novato, CA, USA

I will review recente progress in the study of the aging immune system with a focus on senescence and epigenetic regulation.

Thursday, May 4  | 15:00 – 15:20 pm

Why Longevity Clinicians need a powerful data analysis tool to provide evidence-based, effective longevity support

by James Raaf, Biokineticist and Member of the Healthy Longevity Medicine Society and leads the clinical team at Biolytica AG

Harnessing the skills of longevity physicians, clinicians, bioinformaticians, AI, data development specialists and myriad longevity professionals, we believe that the enormously complex challenge of addressing human aging requires both holistic and integrative perspectives, as well as a novel reductionist approach to deep analytics.
 

Thursday, May 4  | 15:40 – 16:00 pm

Artificial Intelligence (AI) in Longevity Medicine Restoring to Biological Age of an Individual Performance

by Evelyne Bischof, MD, MPF, FEFIM, University Hospital Renji of Jiatong University, Shangai, PRC

Longevity medicine is AI—driven precision medicine aiming at expanding the healthy lifespan by identifying the risks of diseases, mitigating and eliminating them. Longevity industry has been named one of the next trillion-dollar industry. China is one of the absolute global leaders in longevity and healthy aging, Recent advances in deep learning enabled the development of AI systems that outperform humans in many tasks and have started to empower scientists and physicians with new tools. In this talk, Prof. Dr. med. Evelyne Yehudit Bischof, discusses what is applied longevity medicine, how she leads her longevity patients in China and worldwide, and which and how exponentially growing applications of AI are emerging in the field of longevity.

Friday, May 5  | 11:30 – 11:50 am

More than just skin deep: the impact of collagen on healthspan and lifespan

Pascal Rode, Co-Founder and COO of Avea Life.

Friday, May 5  | 17:00 – 17:20 pm

Opportunities and challenges of longevity bioactives as part of F&B solutions at global scale

by Philipp Gut, M.D. and Head of Data Sciences and Precision Nutrition Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland

Prevention through nutritional approaches, sometimes referred to as food as medicine, is gaining in importance to address a broad range of non-communicable diseases.  Among such strategies is the use of bioactive molecules from edible sources that can be enriched in supplements, foods, or beverages to complement balanced eating patterns. In this talk, I will summarize opportunities around emerging “longevity bioactives” that target cellular hallmarks of aging to illustrate the potential but also the challenges to use them as part of Food & Beverage (F&B) solutions at a global scale.

Friday, May 5  | 15:10 – 15:30 pm

P4 Medicine: how Systems Biology will transform Healthcare and Society

By Dr. Michael Sagner, MD, Director of the Board of the European Society of Preventive Medicine, Oxford, UK

Ten years ago, the proposition that healthcare is evolving from reactive disease care to care that is predictive, preventive, personalized and participatory was regarded as highly speculative. Today, the core elements of that vision are widely accepted and have been articulated in a series of recent reports by the US Institute of Medicine. Systems approaches to biology and medicine are now beginning to provide patients, consumers and physicians with personalized information about each individual’s unique health experience of both health and disease at the molecular, cellular and organ levels. This information will make disease care radically more cost effective by personalizing care to each person’s unique biology and by treating the causes rather than the symptoms of disease. It will also provide the basis for concrete action by consumers to improve their health as they observe the impact of lifestyle decisions. Working together in digitally powered familial and affinity networks, consumers will be able to reduce the incidence of the complex chronic diseases that currently account for 75% of disease-care costs in the world.